A Study of Debio 025 in Combination With PegIFN Alpha-2a and Ribavirin in Chronic HCV Patients Non-responders to Standard Treatment

An Open-label, Randomized, 5-arm, Parallel-group Study of the Effects on Viral Kinetics, Safety and Pharmacokinetics of Different Dosing Regimens of Debio 025 in Combination With Peginterferon Alpha-2a and Ribavirin in Chronic HCV Genotype 1 Patients Who Are Non Responders to Standard Peginterferon Alpha and Ribavirin Treatment

Debio 025 (alisporivir) is an oral cyclophilin inhibitor with a new mechanism of action demonstrating potent anti-hepatitis C virus (HCV) activity in pre-clinical models and patients.

The current standard of care (SOC) in HCV patients consists of a combination of peg-IFN alpha and ribavirin. Treatment duration and ribavirin dose depend on the genotype treated. Only 40-50% of patients with genotype 1 achieve a sustained viral response (SVR). This study assesses whether Debio 025 administered in combination with peg-IFN alpha 2a and ribavirin can improve the outcome of treatment in this group of patients.

Study Overview

• Status: Completed
• Conditions: Chronic Hepatitis C
• Intervention / Treatment: Drug: Debio 025; Drug: Peg-IFNα2a; Drug: Ribavirin

Detailed Description

This is a multicentre, open-label, randomized, 5 arm parallel-group, multiple dose study in 50 chronic hepatitis C virus (HCV) genotype 1 non-responders to standard treatment with peg-IFN alpha (2a or 2b) and ribavirin. The entire study lasts a maximum of 96 weeks and consists of a 48- or 72-week treatment period (according to response). A follow-up visit to assess the sustained viral response (SVR) takes place 24 weeks after treatment cessation, i.e., at study Week 72 or 96, or earlier for discontinued study participants.

There were 2 parts in the treatment period. Part 1 lasted from Day 1 to Day 29 (Weeks 1 to 4); Part 2 lasted from Week 5 to Week 48 or 72.

During Part 1 of treatment (Weeks 1 to 4), participants are randomized to 1 of 5 treatment arms and receive 4 weeks of Debio 025 (alisporivir) monotherapy, Debio 025 combined with standard dose peg-IFNα2a, or 1 of 3 triple therapies combining different doses of Debio 025 with peg-IFNα2a and ribavirin at standard doses.

During Part 2 of treatment (Weeks 5 to 48 or 72), participants receive standard doses of peg-IFNα2a/ribavirin dual therapy for 44 or 68 weeks, depending on their response to treatment. At Week 12, participants who do not achieve ≥ 2 log10 decrease in HCV RNA are withdrawn and considered treatment failures. Participants who have undetectable HCV RNA levels and/or ≥ 2 log10 decrease in HCV RNA continue treatment until Week 24. At Week 24, participants who still have detectable HCV RNA levels are withdrawn and considered treatment failures. Participants with undetectable HCV RNA levels at Weeks 12 and 24 continue treatment until Week 48. At Week 24, "slow responders" (defined as participants with a detectable, but > 2 log10 decrease in HCV RNA levels at Week 12 and undetectable levels at Week 24) are eligible to continue treatment until Week 72.

• Study Type: Interventional
• Enrollment (Actual): 50
• Phase: Phase 2

Contacts and Locations

Study Locations

• United States
  • California
    • la Jolla, California, United States, 92037
      • Scripps Clinic Liver Disease Research Center
  • Florida
    • Gainesville, Florida, United States, 32610
      • University of Florida
    • Miami, Florida, United States, 33136
      • University of Miami Center for Liver Diseases
  • Maryland
    • Baltimore, Maryland, United States, 21205
      • The Johns Hopkins University School of Medicine
  • Texas
    • Dallas, Texas, United States, 75203
      • Methodist Transplant Physicians
  • Virginia
    • Fairfax, Virginia, United States, 22031
      • Metropolitan Research
  • Washington
    • Seattle, Washington, United States, 98101
      • Virginia Mason Medical Center

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 18 years to 60 years (Adult)
• Accepts Healthy Volunteers: No
• Genders Eligible for Study: All

Description

Inclusion Criteria:

• Male and female patients between 18 and 60 years of age.
• Hepatitis B negative and human immunodeficiency virus (HIV) negative.
• Diagnosed with hepatitis C genotype I and not responsive to treatments such as peginterferon alpha-2a or 2b and ribavirin for at least 12 weeks.
• Adequate liver function (Child-Pugh-Turcotte score A) and other laboratory parameters within acceptable range.
• Females may participate only if they cannot become pregnant, i.e., are surgically sterile, post-menopausal, or using 2 reliable contraceptive methods.
• Male patients must be surgically sterile or utilizing a barrier contraceptive method.
• For female patients of child bearing potential, negative pregnancy test within 1 week of first investigational product administration.

Exclusion Criteria:

• Treatment with any investigational drug within 6 months prior to the start of the study.
• Ongoing or recent use of antiviral medication within 1 month before the start of the study.
• A known bad reaction or intolerance to Debio 025, peginterferon alpha-2a, and/or ribavirin.
• Presence or history of any severe related disease.

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Treatment
• Allocation: Randomized
• Interventional Model: Parallel Assignment
• Masking: None (Open Label)

Number of Arms

5

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
Experimental: Treatment Arm A; Debio 025 (alisporivir) 400 mg orally once daily + peg-IFNα2a 180 μg subcutaneously (sc) once weekly + ribavirin 1000 or 1200 mg/day orally for 29 days followed by peg-IFNα2a 180 μg sc once weekly + ribavirin 1000 or 1200 mg/day orally administered for 44 or 68 weeks depending upon response	Drug: Debio 025; Debio 025 supplied as a 100 mg/mL oral solution; Other Names: Alisporivir; Drug: Peg-IFNα2a; Peg-IFNa2a supplied in 180 μg/0.5 mL prefilled syringes; Other Names: PEGASYS; Drug: Ribavirin; Ribavirin supplied as 200 mg tablets; Other Names: Copegus
Experimental: Treatment Arm B; Debio 025 (alisporivir) 400 mg orally once daily for 29 days followed by peg-IFNα2a 180 μg sc once weekly + ribavirin 1000 or 1200 mg/day orally administered for 44 or 68 weeks depending upon response	Drug: Debio 025; Debio 025 supplied as a 100 mg/mL oral solution; Other Names: Alisporivir; Drug: Peg-IFNα2a; Peg-IFNa2a supplied in 180 μg/0.5 mL prefilled syringes; Other Names: PEGASYS; Drug: Ribavirin; Ribavirin supplied as 200 mg tablets; Other Names: Copegus
Experimental: Treatment Arm C; Debio 025 (alisporivir) 400 mg orally once daily + peg-IFNα2a 180 μg sc once weekly for 29 days followed by peg-IFNα2a 180 μg sc once weekly + ribavirin 1000 or 1200 mg/day orally administered for 44 or 68 weeks depending upon response	Drug: Debio 025; Debio 025 supplied as a 100 mg/mL oral solution; Other Names: Alisporivir; Drug: Peg-IFNα2a; Peg-IFNa2a supplied in 180 μg/0.5 mL prefilled syringes; Other Names: PEGASYS; Drug: Ribavirin; Ribavirin supplied as 200 mg tablets; Other Names: Copegus
Experimental: Treatment Arm D; Debio 025 (alisporivir) 800 mg orally once daily + peg-IFNα2a 180 μg sc once weekly + ribavirin 1000 or 1200 mg/day orally for 29 days followed by peg-IFNα2a 180 μg sc once weekly + ribavirin 1000 or 1200 mg/day orally administered for 44 or 68 weeks depending upon response	Drug: Debio 025; Debio 025 supplied as a 100 mg/mL oral solution; Other Names: Alisporivir; Drug: Peg-IFNα2a; Peg-IFNa2a supplied in 180 μg/0.5 mL prefilled syringes; Other Names: PEGASYS; Drug: Ribavirin; Ribavirin supplied as 200 mg tablets; Other Names: Copegus
Experimental: Treatment Arm E; Debio 025 (alisporivir) orally at a loading dose of 400 mg twice daily for 7 days followed by 400 mg/day for 22 days + peg-IFNα2a 180 μg sc once weekly + ribavirin 1000 or 1200 mg/day orally for 29 days followed by peg-IFNα2a 180 μg sc once weekly + ribavirin 1000 or 1200 mg/day orally administered for 44 or 68 weeks depending upon response	Drug: Debio 025; Debio 025 supplied as a 100 mg/mL oral solution; Other Names: Alisporivir; Drug: Peg-IFNα2a; Peg-IFNa2a supplied in 180 μg/0.5 mL prefilled syringes; Other Names: PEGASYS; Drug: Ribavirin; Ribavirin supplied as 200 mg tablets; Other Names: Copegus

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Change From Baseline in log10 Hepatitis C Virus RNA at Day 29 in the Debio 025 Triple Therapy Treatment Arms (A, D, and E)	Hepatitis C virus RNA was quantified in plasma samples using real time polymerase chain reaction.	Baseline to Day 29

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Change From Baseline in log10 Hepatitis C Virus RNA at Day 29 in the Debio 025 Monotherapy and Dual Therapy Treatment Arms (B and C)	Hepatitis C virus RNA was quantified in plasma samples using real time polymerase chain reaction.	Baseline to Day 29
log10 Hepatitis C Virus RNA at Day 29	Hepatitis C virus RNA was quantified in plasma samples using real time polymerase chain reaction.	Day 29
Percentage of Participants With a Rapid Viral Response at Day 29	A participant had a rapid viral response if their viral RNA was undetectable (< 10 IU/mL).	Day 29
Percentage of Participants With an Early Viral Response at Week 12	A participant had an early viral response if their viral RNA had decreased ≥ 2 log10 at Week 12 compared to Baseline.	Baseline to Week 12
Percentage of Participants With an End-of-treatment Response at the End of Treatment (Week 48 or 72)	A participant had an end-of-treatment response if their viral RNA was undetectable (< 10 IU/mL).	End of treatment (Week 48 or 72)
Percentage of Participants With a Sustained Viral Response 24 Weeks After the End of Treatment (Week 72 or 96)	A participant had a sustained viral response if their viral RNA was undetectable (< 10 IU/mL).	24 weeks after the end of treatment (Week 72 or 96)

Collaborators and Investigators

• Sponsor: Debiopharm International SA
• Investigators: Study Director: Raf Crabbé, MD, Debiopharm International S.A.

Study record dates

Study Major Dates

• Study Start: September 1, 2007
• Primary Completion (Actual): April 1, 2010
• Study Completion (Actual): April 1, 2010

Study Registration Dates

• First Submitted: September 28, 2007
• First Submitted That Met QC Criteria: September 28, 2007
• First Posted (Estimate): October 1, 2007

Study Record Updates

• Last Update Posted (Estimate): February 17, 2016
• Last Update Submitted That Met QC Criteria: February 12, 2016
• Last Verified: February 1, 2016

More Information

Terms related to this study

• Keywords: Hepatitis C; Hepatitis
• Additional Relevant MeSH Terms: Digestive System Diseases; RNA Virus Infections; Virus Diseases; Infections; Blood-Borne Infections; Communicable Diseases; Liver Diseases; Flaviviridae Infections; Hepatitis, Viral, Human; Hepatitis, Chronic; Hepatitis; Hepatitis C; Hepatitis C, Chronic; Molecular Mechanisms of Pharmacological Action; Anti-Infective Agents; Antiviral Agents; Antimetabolites; Ribavirin; Peginterferon alfa-2a
• Other Study ID Numbers: Debio 025-HCV-207; DEB025A2207 (Other Identifier: Sponsor Code)